Examination of the emerging role of transporters in the assessment of nephrotoxicity

References

• Wirthensohn G, Guder WG. Renal substrate metabolism. Physiol Rev. 1986;66(2):469–497.
   PubMed Web of Science ®Google Scholar
• Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int. 1984;26(2):101–111.
   PubMed Web of Science ®Google Scholar
• Fisel P, Renner O, Nies AT, et al. Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. Expert Opin Drug Metab Toxicol. 2014;10(3):395–408.
   PubMed Web of Science ®Google Scholar
• George B, You D, Joy MS, et al. Xenobiotic transporters and kidney injury. Adv Drug Deliv Rev. 2017;116:73–91.
   PubMed Web of Science ®Google Scholar
• Shen H, Scialis RJ, Lehman-McKeeman L. Xenobiotic transporters in the kidney: function and role in toxicity. Semin Nephrol. 2019;39(2):159–175.
   PubMed Web of Science ®Google Scholar
• Rawls KD, Dougherty BV, Vinnakota KC, et al. Predicting changes in renal metabolism after compound exposure with a genome-scale metabolic model. Toxicol Appl Pharmacol. 2021;412:115390.
   PubMed Web of Science ®Google Scholar
• Cui Y, Han J, Ren J, et al. Untargeted LC-MS-based metabonomics revealed that aristolochic acid I induces testicular toxicity by inhibiting amino acids metabolism, glucose metabolism, β-oxidation of fatty acids and the TCA cycle in male mice. Toxicol Appl Pharmacol. 2019;373:26–38.
   PubMed Web of Science ®Google Scholar
• Xie L, Zhao Y, Duan J, et al. Integrated proteomics and metabolomics reveal the mechanism of nephrotoxicity Induced by Triptolide. Chem Res Toxicol. 2020;33(7):1897–1906.
   PubMed Web of Science ®Google Scholar
• Xu EY, Perlina A, Vu H, et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem Res Toxicol. 2008;21(8):1548–1561.
   PubMed Web of Science ®Google Scholar
• Qu X, Gao H, Sun J, et al. Identification of key metabolites during cisplatin-induced acute kidney injury using an HPLC-TOF/MS-based non-targeted urine and kidney metabolomics approach in rats. Toxicology. 2020;431:152366.
   PubMed Web of Science ®Google Scholar
• Soo JY, Jansen J, Masereeuw R, et al., Advances in predictive in vitro models of drug-induced nephrotoxicity. Nat Rev Nephrol. 2018;14(6): 378–393. .
   PubMed Web of Science ®Google Scholar
• Gozalpour E, Fenner KS. Current state of in vitro cell-based renal models. Curr Drug Metab. 2018;19(4):310–326.
   PubMed Web of Science ®Google Scholar
• Koepsell H. Organic cation transporters in health and disease. Pharmacol Rev. 2020;72(1):253–319.
   PubMed Web of Science ®Google Scholar
• Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacol Ther. 2012;136(1):106–130.
   PubMed Web of Science ®Google Scholar
• Huo X, Liu K. Renal organic anion transporters in drug-drug interactions and diseases. Eur J Pharm Sci. 2018;112:8–19.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang H, Fan Y, et al. Regulation of organic anion transporters: role in physiology, pathophysiology, and drug elimination. Pharmacol Ther. 2021;217:107647.
   PubMed Web of Science ®Google Scholar
• Gründemann D, Gorboulev V, Gambaryan S, et al. Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994;372(6506):549–552.
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16(7):871–881.
   PubMed Web of Science ®Google Scholar
• Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51(6):913–921.
   PubMed Web of Science ®Google Scholar
• Urakami Y, Kimura N, Okuda M, et al. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004;21(6):976–981.
   PubMed Web of Science ®Google Scholar
• Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22(2):255–259.
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Ludwig T, Lang D, et al., Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005;167(6): 1477–1484. .
   PubMed Web of Science ®Google Scholar
• Pochini L, Galluccio M, Scalise M, et al. OCTN: a small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics. SLAS Discov. 2019;24(2):89–110.
   PubMed Web of Science ®Google Scholar
• Motohashi H, Inui K. Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol Aspects Med. 2013;34(2–3):661–668.
   PubMed Web of Science ®Google Scholar
• Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38(7–8):802–832.
   PubMed Web of Science ®Google Scholar
• Ivanyuk A, Livio F, Biollaz J, et al. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825–892.
   PubMed Web of Science ®Google Scholar
• Srimaroeng C, Perry JL, Pritchard JB. Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica. 2008;38(7–8):889–935.
   PubMed Web of Science ®Google Scholar
• Cha SH, Sekine T, Fukushima JI, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001;59(5):1277–1286.
   PubMed Web of Science ®Google Scholar
• Motojima M, Hosokawa A, Yamato H, et al. Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake. Br J Pharmacol. 2002;135(2):555–563.
   PubMed Web of Science ®Google Scholar
• Khamdang S, Takeda M, Noshiro R, et al. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002;303(2):534–539.
   PubMed Web of Science ®Google Scholar
• Takeda M, Babu E, Narikawa S, et al. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002;450(1):111.
   Web of Science ®Google Scholar
• Uwai Y, Ida H, Tsuji Y, et al. Renal transport of Adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007;24(4):811–815.
   PubMed Web of Science ®Google Scholar
• Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004;101(10):3569–3574.
   PubMed Web of Science ®Google Scholar
• Bakos E, Evers R, Sinkó E, et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000;57(4):760–768.
   PubMed Web of Science ®Google Scholar
• Caetano-Pinto P, Jansen J, Assaraf YG, et al. The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. Drug Resist Updat. 2017;30:15–27.
   PubMed Web of Science ®Google Scholar
• Filipski KK, Loos WJ, Verweij J, et al. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008;14(12):3875–3880.
   PubMed Web of Science ®Google Scholar
• Ishida S, Lee J, Thiele Dennis J, et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002;99(22):14298–14302.
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319(2):879.
   PubMed Web of Science ®Google Scholar
• Wen X, Buckley B, McCandlish E, et al. Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol. 2014;184(5):1299–1308.
   PubMed Web of Science ®Google Scholar
• Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002;302(2):666.
   PubMed Web of Science ®Google Scholar
• de Graaf D, Sharma RC, Mechetner EB, et al. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci U S A. 1996;93(3):1238–1242.
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Kool M, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59(11):2532–2535.
   PubMed Web of Science ®Google Scholar
• van Aubel Ramh, Smeets PHE, Peters PHE, et al. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002;13(3):595–603.
   PubMed Web of Science ®Google Scholar
• Otter M, Csader S, Keiser M, et al. Expression and functional contribution of different organic cation transporters to the cellular uptake of doxorubicin into human breast cancer and cardiac tissue. Int J Mol Sci. 2022;23(1):255.
   Web of Science ®Google Scholar
• Lee HH, Leake BF, Kim RB, et al. Contribution of organic anion-transporting polypeptides 1A/1B to doxorubicin uptake and clearance. Mol Pharmacol. 2017;91(1):14.
   PubMed Web of Science ®Google Scholar
• Cihlar T, Ho ES. Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000;283(1):49–55.
   PubMed Web of Science ®Google Scholar
• Cihlar T, LaFlamme G, Fisher R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009;53(1):150–156.
   PubMed Web of Science ®Google Scholar
• Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs Adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619.
   PubMed Web of Science ®Google Scholar
• Zou L, Stecula A, Gupta A, et al. Molecular mechanisms for species differences in organic anion transporter 1, OAT1: implications for renal drug toxicity. Mol Pharmacol. 2018;94(1):689.
   PubMed Web of Science ®Google Scholar
• Ye J, Liu Q, Wang C, et al. Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3. Pharmacol Rep. 2013;65(2):505–512.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Vapurcuyan A, Shahidullah M, et al. Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012;40(3):617.
   PubMed Web of Science ®Google Scholar
• Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem Pharmacol. 2007;74(2):359–371.
   PubMed Web of Science ®Google Scholar
• Huo X, Meng Q, Wang C, et al. Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs). Acta Pharm Sin B. 2019;9(5):986–996.
   PubMed Web of Science ®Google Scholar
• Lu X, Chan T, Xu C, et al. Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. J Antimicrob Chemother. 2016;71(2):403–412.
   PubMed Web of Science ®Google Scholar
• Visentin M, Gai Z, Torozi A, et al. Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017;45(12):1240.
   PubMed Web of Science ®Google Scholar
• Zou L, Matsson P, Stecula A, et al. Drug metabolites potently inhibit renal organic anion transporters, OAT1 and OAT3. J Pharm Sci. 2021;110(1):347–353.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Han YH, Putluru SP, et al. Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro. Drug Metab Dispos. 2016;44(3):320.
   PubMed Web of Science ®Google Scholar
• Xue X, Gong LK, Maeda K, et al. Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol Pharm. 2011;8(6):2183–2192.
   PubMedGoogle Scholar
• Li LP, Song FF, Weng YY, et al. Role of OCT2 and MATE1 in renal disposition and toxicity of nitidine chloride. Br J Pharmacol. 2016;173(16):2543–2554.
   PubMed Web of Science ®Google Scholar
• Shen Q, Wang J, Yuan Z, et al. Key role of organic cation transporter 2 for the nephrotoxicity effect of triptolide in rheumatoid arthritis. Int Immunopharmacol. 2019;77:105959.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Sekine T, Takeda M, et al. Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999;289(3):1301.
   PubMed Web of Science ®Google Scholar
• Jung KY, Takeda M, Kim DK, et al. Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001;69(18):2123–2135.
   PubMed Web of Science ®Google Scholar
• Babu E, Takeda M, Narikawa S, et al. Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002;1590(1):64–75.
   PubMed Web of Science ®Google Scholar
• Qi X, Wagenaar E, Xu W, et al. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1. Toxicol Appl Pharmacol. 2017;329:18–25.
   PubMed Web of Science ®Google Scholar
• Soodvilai S, Nantavishit J, Muanprasat C, et al. Renal organic cation transporters mediated cadmium-induced nephrotoxicity. Toxicol Lett. 2011;204(1):38–42.
   PubMed Web of Science ®Google Scholar
• Thévenod F, Ciarimboli G, Leistner M, et al. Substrate- and cell contact-dependent inhibitor affinity of human organic cation transporter 2: studies with two classical organic cation substrates and the novel substrate cd2+. Mol Pharm. 2013;10(8):3045–3056.
   PubMedGoogle Scholar
• Yang H, Guo D, Obianom ON, et al. Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicol Appl Pharmacol. 2017;314:55–62.
   PubMed Web of Science ®Google Scholar
• Zalups RK, Ahmad S. Homocysteine and the renal epithelial transport and toxicity of inorganic mercury: role of basolateral transporter organic anion transporter 1. J Am Soc Nephrol. 2004;15(8):2023.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Joshee L, Bridges CC. MRP2 and the transport kinetics of cysteine conjugates of inorganic mercury. Biol Trace Elem Res. 2018;184(1):279–286.
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007.
   PubMed Web of Science ®Google Scholar
• Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15–25.
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010;176(3):1169–1180.
   PubMed Web of Science ®Google Scholar
• Guo D, Yang H, Li Q, et al. Selective inhibition on organic cation transporters by carvedilol protects mice from cisplatin-induced nephrotoxicity. Pharm Res. 2018;35(11):204.
   PubMed Web of Science ®Google Scholar
• Gao H, Zhang S, Hu T, et al. Omeprazole protects against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and transporter-mediated cisplatin accumulation in rats and HK-2 cells. Chem Biol Interact. 2019;297:130–140.
   PubMed Web of Science ®Google Scholar
• Li C, Li L, Yi Y, et al. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy. Biochem Pharmacol. 2020;177:114021.
   PubMed Web of Science ®Google Scholar
• Huang D, Wang C, Duan Y, et al. Targeting Oct2 and P53: formononetin prevents cisplatin-induced acute kidney injury. Toxicol Appl Pharmacol. 2017;326:15–24.
   PubMed Web of Science ®Google Scholar
• Liu YH, Li K, Tian HQ. Renoprotective effects of a new free radical scavenger, XH-003, against cisplatin-induced nephrotoxicity. Oxid Med Cell Longev. 2020;2020:9820168.
   PubMed Web of Science ®Google Scholar
• Ishida S, McCormick F, Smith-McCune K, et al. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010;17(6):574–583.
   PubMed Web of Science ®Google Scholar
• Hu S, Leblanc AF, Gibson AA, et al. Identification of OAT1/OAT3 as contributors to cisplatin toxicity. Clin Transl Sci. 2017;10(5):412–420.
   PubMed Web of Science ®Google Scholar
• Fda.gov [Internet]. United States: congress of the United States; [cited 2020 Oct 3]. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/
   Google Scholar
• Nozaki Y, Kusuhara H, Endou H, et al. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther. 2004;309(1):226.
   PubMed Web of Science ®Google Scholar
• Ueda H, Narumi K, Sato Y, et al. Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. Pharmacol Rep. 2020;72(5):1426–1432.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang Y, Wang P, et al. Adefovir accumulation and nephrotoxicity in renal interstitium: role of organic anion transporters of kidney. Life Sci. 2019;224:41–50.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wei M, Zhang M, et al. Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis. Toxicol Lett. 2022;359:10–21.
   PubMed Web of Science ®Google Scholar
• Brandoni A, Villar SR, Picena JC, et al. Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction. Hepatology. 2006;43(5):1092–1100.
   PubMed Web of Science ®Google Scholar
• Micuda S, Brcakova E, Fuksa L, et al. P-glycoprotein function and expression during obstructive cholestasis in rats. Eur J Gastroenterol Hepatol. 2008;20(5):404–412.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kobayashi Y, Gabazza EC, et al. Increased renal expression of bilirubin glucuronide transporters in a rat model of obstructive jaundice. Am J Physiol Gastrointest Liver Physiol. 2002;282(4):G656–G662.
   PubMed Web of Science ®Google Scholar
• Denk GU, Soroka CJ, Takeyama Y, et al. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol. 2004;40(4):585–591.
   PubMed Web of Science ®Google Scholar
• Canet MJ, Hardwick RN, Lake AD, et al. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis. Drug Metab Dispos. 2015;43(2):266.
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Morisaki T, Sugimoto W, et al. Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury. Drug Metab Dispos. 2008;36(4):649.
   PubMed Web of Science ®Google Scholar
• Matsuzaki T, Watanabe H, Yoshitome K, et al. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure. Kidney Int. 2007;71(6):539–547.
   PubMed Web of Science ®Google Scholar
• Ji L, Masuda S, Saito H, et al. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 2002;62(2):514–524.
   PubMed Web of Science ®Google Scholar
• Laouari D, Yang R, Veau C, et al. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol. 2001;280(4):F636–F645.
   PubMed Web of Science ®Google Scholar
• Nishizawa K, Yoda N, Morokado F, et al. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia. PLoS One. 2019;14(4):e0214862–e0214862.
   PubMed Web of Science ®Google Scholar
• Habu Y, Yano I, Takeuchi A, et al. Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem Pharmacol. 2003;66(6):1107–1114.
   PubMed Web of Science ®Google Scholar
• More VR, Wen X, Thomas PE, et al. Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice. Comparative Hepatology. 2012;11(1):1.
   PubMedGoogle Scholar
• Cheng Q, Aleksunes LM, Manautou JE, et al. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm. 2008;5(1):77–91.
   PubMed Web of Science ®Google Scholar
• Komazawa H, Yamaguchi H, Hidaka K, et al. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. J Pharm Sci. 2013;102(3):1086–1094.
   PubMed Web of Science ®Google Scholar
• Naud J, Michaud J, Beauchemin S, et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos. 2011;39(8):1363.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Masuda S, Saito H, et al. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int. 2001;60(3):1058–1068.
   PubMed Web of Science ®Google Scholar
• Ben Salem C, Slim R, Fathallah N, et al. Drug-induced hyperuricaemia and gout. Rheumatology. 2017;56(5):679–688.
   PubMed Web of Science ®Google Scholar
• Gai Z, Visentin M, Hiller C, et al. Organic cation transporter 2 overexpression may confer an increased risk of gentamicin-induced nephrotoxicity. Antimicrob Agents Chemother. 2016;60(9):5573–5580.
   PubMed Web of Science ®Google Scholar
• Jilek JL, Frost KL, Jacobus KA, et al. Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. Acta Pharm Sin B. 2021;11(12):3869–3878.
   PubMed Web of Science ®Google Scholar
• Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142.
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32–43.
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434.
   PubMed Web of Science ®Google Scholar
• Wang XX, Levi J, Luo Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem. 2017;292(13):5335–5348.
   PubMed Web of Science ®Google Scholar
• Chao EC, Henry RR. SGLT2 inhibition— anovel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559.
   PubMed Web of Science ®Google Scholar
• Hahn K, Ejaz AA, Kanbay M, et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12(12):711–712.
   PubMed Web of Science ®Google Scholar
• Saly DL, Perazella MA. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Am J Physiol Renal Physiol. 2017;313(4):F951–F954.
   PubMed Web of Science ®Google Scholar
• Jackson J, Chen C, Buising K. Aminoglycosides: how should we use them in the 21st century? Curr Opin Infect Dis. 2013;26(6):516–525.
   PubMed Web of Science ®Google Scholar
• Grégoire N, Aranzana-Climent V, Magréault S, et al. Clinical pharmacokinetics and pharmacodynamics of colistin. Clin Pharmacokinet. 2017;56(12):1441–1460.
   PubMed Web of Science ®Google Scholar
• Jiang M, Wang Q, Karasawa T, et al. Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides. PLoS One. 2014;9(9):e108941–e108941.
   PubMed Web of Science ®Google Scholar
• Samodelov SL, Visentin M, Gai Z, et al. Renal glycosuria as a novel early sign of colistin-induced kidney damage in mice. Antimicrob Agents Chemother. 2019;63(12):e01650–19.
   PubMed Web of Science ®Google Scholar
• Xu Y, Xie Y, Shao X, et al. L-FABP: a novel biomarker of kidney disease. Clin Chim Acta. 2015;445:85–90.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kamijo-Ikemori A, Sugaya T, et al. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol. 2009;174(6):2096–2106.
   PubMed Web of Science ®Google Scholar
• Yang X, Okamura DM, Lu X, et al. CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol. 2017;13(12):769–781.
   PubMed Web of Science ®Google Scholar
• Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21(1):37–46.
   PubMed Web of Science ®Google Scholar
• Hua W, Huang H-Z, Tan L-T, et al. CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress. PLoS One. 2015;10(5):e0127507–e0127507.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Bryl E, Marzec L, et al. Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs. 2005;29(8):608–614.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chen JS, Lin SH, et al. Aberrant activation of the TNF-alpha system and production of Fas and scavenger receptors on monocytes in patients with end-stage renal disease. Artif Organs. 2005;29(9):701–707.
   PubMed Web of Science ®Google Scholar
• Pennathur S, Pasichnyk K, Bahrami NM, et al. The macrophage phagocytic receptor CD36 promotes fibrogenic pathways on removal of apoptotic cells during chronic kidney injury. Am J Pathol. 2015;185(8):2232–2245.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang T, Geng J, et al. Advanced oxidation protein products promote lipotoxicity and tubulointerstitial fibrosis via CD36/β-Catenin pathway in diabetic nephropathy. Antioxid Redox Signal. 2019;31(7):521–538.
   PubMed Web of Science ®Google Scholar
• Feng L, Gu C, Li Y, et al. High glucose promotes CD36 expression by upregulating peroxisome proliferator-activated receptor γ levels to exacerbate lipid deposition in renal tubular cells. Biomed Res Int. 2017;2017:1414070.
   PubMed Web of Science ®Google Scholar
• Melton EM, Cerny RL, Watkins PA, et al. Human fatty acid transport protein 2a/very long chain acyl-CoA synthetase 1 (FATP2a/Acsvl1) has a preference in mediating the channeling of exogenous n-3 fatty acids into phosphatidylinositol. J Biol Chem. 2011;286(35):30670–30679.
   PubMed Web of Science ®Google Scholar
• Khan S, Abu Jawdeh BG, Goel M, et al. Lipotoxic disruption of NHE1 interaction with PI(4,5)P2 expedites proximal tubule apoptosis. J Clin Invest. 2014;124(3):1057–1068.
   PubMed Web of Science ®Google Scholar
• Khan S, Cabral PD, Schilling WP, et al. Kidney proximal tubule lipoapoptosis is regulated by fatty acid transporter-2 (FATP2). J Am Soc Nephrol. 2018;29(1):81–91.
   PubMed Web of Science ®Google Scholar
• Qiu P, Wang H, Zhang M, et al. FATP2-targeted therapies - A role beyond fatty liver disease. Pharmacol Res. 2020;161:105228.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yan Q, Lv M, et al. Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis. Cell Death Dis. 2020;11(11):994.
   PubMed Web of Science ®Google Scholar
• Khan S, Gaivin R, Abramovich C, et al. Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression. JCI Insight. 2020;5(15):e136845.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385–1393.
   PubMed Web of Science ®Google Scholar
• Cheng L, Ge M, Lan Z, et al., Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018;92(1): 469–485. .
   PubMed Web of Science ®Google Scholar
• Simon N, Hertig A. Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis. Front Med (Lausanne). 2015;2:52.
   PubMed Web of Science ®Google Scholar
• Jang HS, Noh MR, Kim J, et al. Defective mitochondrial fatty acid oxidation and lipotoxicity in kidney diseases. Front Med (Lausanne). 2020;7:65.
   PubMed Web of Science ®Google Scholar
• Vaz FM, Wanders RJA. Carnitine biosynthesis in mammals. Biochem J. 2002;361(3):417–429.
   PubMedGoogle Scholar
• Reuter SE, Evans AM. Carnitine and acylcarnitines. Clin Pharmacokinet. 2012;51(9):553–572.
   PubMed Web of Science ®Google Scholar
• Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999;21(1):91–94.
   PubMed Web of Science ®Google Scholar
• Longo N, Amat Di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142C(2):77–85.
   PubMed Web of Science ®Google Scholar
• Lheureux PER, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009;47(2):101–111.
   PubMed Web of Science ®Google Scholar
• Hu C, Lancaster CS, Zuo Z, et al. Inhibition of OCTN2-mediated transport of carnitine by etoposide. Mol Cancer Ther. 2012;11(4):921–929.
   PubMed Web of Science ®Google Scholar
• Ganapathy ME, Huang W, Rajan DP, et al. β-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000;275(3):1699–1707.
   PubMed Web of Science ®Google Scholar
• Portilla D, Dai G, McClure T, et al. Alterations of PPARα and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int. 2002;62(4):1208–1218.
   PubMed Web of Science ®Google Scholar
• Lancaster CS, Hu C, Franke RM, et al. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res. 2010;16(19):4789–4799.
   PubMed Web of Science ®Google Scholar
• Lou Y, Li J, Lu Y, et al. Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats. Toxicol Lett. 2011;201(1):72–79.
   PubMed Web of Science ®Google Scholar
• Durkan AM, Alexander RT. Acute kidney injury post neonatal asphyxia. J Pediatr. 2011;158(2, Suppl):e29–e33.
   PubMedGoogle Scholar
• Wang AG, Diamond M, Waddell J, et al. Effect of acetyl-l-carnitine used for protection of neonatal hypoxic-ischemic brain injury on acute kidney changes in male and female rats. Neurochem Res. 2019;44(10):2405–2412.
   PubMed Web of Science ®Google Scholar
• Xu P, Chen C, Zhang Y, et al. Erythrocyte transglutaminase-2 combats hypoxia and chronic kidney disease by promoting oxygen delivery and carnitine homeostasis. Cell Metab. 2022;34(2):299–316.e6.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan S, Ji C, et al. Metabolomic changes and protective effect of (L)-carnitine in rat kidney ischemia/reperfusion injury. Kidney Blood Press Res. 2012;35(5):373–381.
   PubMed Web of Science ®Google Scholar
• Abu Ahmad N, Armaly Z, Berman S, et al. l-Carnitine improves cognitive and renal functions in a rat model of chronic kidney disease. Physiol Behav. 2016;164:182–188.
   PubMed Web of Science ®Google Scholar
• Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318–328.
   PubMed Web of Science ®Google Scholar
• Su HY, Yang C, Liang D, et al. Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int. 2020;2020:5817348.
   PubMed Web of Science ®Google Scholar
• Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–371.
   PubMed Web of Science ®Google Scholar
• Vallon V, Rieg T, Ahn SY, et al. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008;294(4):F867–F873.
   PubMed Web of Science ®Google Scholar
• Jutabha P, Anzai N, Kitamura K, et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010;285(45):35123–35132.
   PubMed Web of Science ®Google Scholar
• Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007;18(2):430.
   PubMed Web of Science ®Google Scholar
• El-Sheikh AA, Van Den Heuvel JJ, Koenderink JB, et al. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol. 2008;155(7):1066–1075.
   PubMed Web of Science ®Google Scholar
• Bahn A, Hagos Y, Reuter S, et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem. 2008;283(24):16332–16341.
   PubMed Web of Science ®Google Scholar
• Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23(7):1258–1270.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Poesen R, Meijers B. The gut–kidney axis. Pediatr Nephrol. 2017;32(11):2005–2014.
   PubMed Web of Science ®Google Scholar
• Yang T, Richards EM, Pepine CJ, et al. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol. 2018;14(7):442–456.
   PubMed Web of Science ®Google Scholar
• Wu W, Bush KT, Nigam SK. Key role for the organic anion transporters, OAT1 and OAT3, in the in vivo handling of uremic toxins and solutes. Sci Rep. 2017;7(1):4939.
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Nagle MA, Kouznetsova VL, et al. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res. 2011;10(6):2842–2851.
   PubMed Web of Science ®Google Scholar
• Bush KT, Wu W, Lun C, et al. The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut-liver-kidney axis. J Biol Chem. 2017;292(38):15789–15803.
   PubMed Web of Science ®Google Scholar
• Wu IW, Hsu K-H, Lee -C-C, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26(3):938–947.
   PubMed Web of Science ®Google Scholar
• Tan X, Cao X, Zou J, et al. Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis. Hemodial Int. 2017;21(2):161–167.
   PubMed Web of Science ®Google Scholar
• Aleksunes LM, Augustine LM, Scheffer GL, et al. Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology. 2008;250(2):82–88.
   PubMed Web of Science ®Google Scholar
• Liu T, Meng Q, Wang C, et al. Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats. Toxicol Appl Pharmacol. 2012;264(3):423–430.
   PubMed Web of Science ®Google Scholar
• Won AJ, Kim S, Kim YG, et al. Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury. Mol Biosyst. 2016;12(1):133–144.
   PubMedGoogle Scholar
• Wang J, Pan Y, Hong Y, et al. Quercetin protects against cadmium-induced renal uric acid transport system alteration and lipid metabolism disorder in rats. Evid Based Complement Alternat Med. 2012;2012:548430.
   PubMed Web of Science ®Google Scholar
• Ljubojević M, Breljak D, Herak-Kramberger CM, et al. Expression of basolateral organic anion and cation transporters in experimental cadmium nephrotoxicity in rat kidney. Arch Toxicol. 2016;90(3):525–541.
   PubMed Web of Science ®Google Scholar
• Lan Z, Bi KS, Chen XH. Ligustrazine attenuates elevated levels of indoxyl sulfate, kidney injury molecule-1 and clusterin in rats exposed to cadmium. Food Chem Toxicol. 2014;63:62–68.
   PubMed Web of Science ®Google Scholar
• Yu CP, Sweet DH, Peng YH, et al. Effects of nonsteroidal anti-inflammatory drugs on the renal excretion of indoxyl sulfate, a nephro-cardiovascular toxin, in rats. Eur J Pharm Sci. 2017;101:66–70.
   PubMed Web of Science ®Google Scholar
• Luo SS, Yu CP, Hsieh YW, et al. Effects of antibiotics on the pharmacokinetics of indoxyl sulfate, a nephro-cardiovascular toxin. Xenobiotica. 2020;50(5):588–592.
   PubMed Web of Science ®Google Scholar
• Granados JC, Richelle A, Gutierrez JM, et al. Coordinate regulation of systemic and kidney tryptophan metabolism by the drug transporters OAT1 and OAT3. J Biol Chem. 2021;296:100575.
   PubMed Web of Science ®Google Scholar
• André C, Mernissi T, Choukroun G, et al. The prescription of drugs that inhibit organic anion transporters 1 or 3 is associated with the plasma accumulation of uremic toxins in kidney transplant recipients. Toxins (Basel). 2021;14(1):15.
   PubMed Web of Science ®Google Scholar
• Kashani K, Rosner MH, Ostermann M. Creatinine: from physiology to clinical application. Eur J Intern Med. 2020;72:9–14.
   PubMed Web of Science ®Google Scholar
• Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol. 2016;27(1):305–313.
   PubMed Web of Science ®Google Scholar
• Missailidis C, Hällqvist J, Qureshi AR, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS One. 2016;11(1):e0141738–e0141738.
   PubMed Web of Science ®Google Scholar
• Janeiro MH, Ramírez MJ, Milagro FI, et al. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398.
   PubMed Web of Science ®Google Scholar
• Teft WA, Morse BL, Leake BF, et al. Identification and characterization of trimethylamine-N-oxide uptake and efflux transporters. Mol Pharm. 2017;14(1):310–318.
   PubMed Web of Science ®Google Scholar
• Taghikhani E, Maas R, Fromm MF, et al. The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine. PLoS One. 2019;14(3):e0213747–e0213747.
   PubMed Web of Science ®Google Scholar
• Jacobi J, Tsao PS. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol. 2008;28(2):224–237.
   PubMed Web of Science ®Google Scholar
• Tain YL, Hsu CN. Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins (Basel). 2017;9(3):92.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Böger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113–2117.
   PubMed Web of Science ®Google Scholar
• Toyohara T, Suzuki T, Morimoto R, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol. 2009;20(12):2546–2555.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Saigusa D, Kanemitsu Y, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019;10(1):1835.
   PubMedGoogle Scholar
• Ryan MJ, Johnson G, Kirk J, et al. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 1994;45(1):48–57.
   PubMed Web of Science ®Google Scholar
• Jenkinson SE, Chung GW, van Loon E, et al. The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule. Pflugers Arch. 2012;464(6):601–611.
   PubMed Web of Science ®Google Scholar
• DesRochers TM, Suter L, Roth A, et al. Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity. PLoS One. 2013;8(3):e59219–e59219.
   PubMed Web of Science ®Google Scholar
• Aschauer L, Carta G, Vogelsang N, et al. Expression of xenobiotic transporters in the human renal proximal tubule cell line RPTEC/TERT1. Toxicol In Vitro. 2015;30(1, Pt A):95–105.
   PubMed Web of Science ®Google Scholar
• Wilmer MJ, Saleem MA, Masereeuw R, et al. Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res. 2010;339(2):449–457.
   PubMed Web of Science ®Google Scholar
• Jansen J, Schophuizen CMS, Wilmer MJ, et al. A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue. Exp Cell Res. 2014;323(1):87–99.
   PubMed Web of Science ®Google Scholar
• Narayanan K, Schumacher KM, Tasnim F, et al. Human embryonic stem cells differentiate into functional renal proximal tubular-like cells. Kidney Int. 2013;83(4):593–603.
   PubMed Web of Science ®Google Scholar
• Li Y, Kandasamy K, Chuah JKC, et al. Identification of nephrotoxic compounds with embryonic stem-cell-derived human renal proximal tubular-like cells. Mol Pharm. 2014;11(7):1982–1990.
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Chuah JKC, Su R, et al. Prediction of drug-induced nephrotoxicity and injury mechanisms with human induced pluripotent stem cell-derived cells and machine learning methods. Sci Rep. 2015;5(1):12337.
   PubMedGoogle Scholar
• Sato T, Masuda S, Yonezawa A, et al. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol. 2008;76(7):894–903.
   PubMed Web of Science ®Google Scholar
• König J, Zolk O, Singer K, et al. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol. 2011;163(3):546–555.
   PubMed Web of Science ®Google Scholar
• Wieser M, Stadler G, Jennings P, et al. hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol. 2008;295(5):F1365–F1375.
   PubMed Web of Science ®Google Scholar
• Wilmes A, Limonciel A, Aschauer L, et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics. 2013;79:180–194.
   PubMed Web of Science ®Google Scholar
• Aschauer L, Limonciel A, Wilmes A, et al. Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: a transcriptomic study. Toxicol in Vitro. 2015;30(1, Pt A):106–116.
   PubMed Web of Science ®Google Scholar
• Nieskens TT, Peters JG, Schreurs MJ, et al. A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity. AAPS J. 2016;18(2):465–475.
   PubMed Web of Science ®Google Scholar
• Brown CD, Sayer R, Windass AS, et al. Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol. 2008;233(3):428–438.
   PubMed Web of Science ®Google Scholar
• Li Y, Oo ZY, Chang SY, et al. An in vitro method for the prediction of renal proximal tubular toxicity in humans. Toxicol Res. 2013;2(5):352–365.
   Web of Science ®Google Scholar
• Adler M, Ramm S, Hafner M, et al. A quantitative approach to screen for nephrotoxic compounds in vitro. J Am Soc Nephrol. 2016;27(4):1015–1028.
   PubMed Web of Science ®Google Scholar
• Bajaj P, Chung G, Pye K, et al. Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicity. Toxicology. 2020;442:152535.
   PubMed Web of Science ®Google Scholar
• Jang KJ, Mehr AP, Hamilton GA, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol (Camb). 2013;5(9):1119–1129.
   PubMed Web of Science ®Google Scholar
• Ravi M, Paramesh V, Kaviya SR, et al. 3D cell culture systems: advantages and applications. J Cell Physiol. 2015;230(1):16–26.
   PubMed Web of Science ®Google Scholar
• King SM, Higgins JW, Nino CR, et al. 3D proximal tubule tissues recapitulate key aspects of renal physiology to enable nephrotoxicity testing. Front Physiol. 2017;8:123.
   PubMed Web of Science ®Google Scholar
• Wilmer MJ, Ng CP, Lanz HL, et al. Kidney-on-a-chip technology for drug-induced nephrotoxicity screening. Trends Biotechnol. 2016;34(2):156–170.
   PubMed Web of Science ®Google Scholar
• Nishinakamura R. Human kidney organoids: progress and remaining challenges. Nat Rev Nephrol. 2019;15(10):613–624.
   PubMed Web of Science ®Google Scholar
• Mahadeo A, Yeung CK, Himmelfarb J, et al. Kidney microphysiological models for nephrotoxicity assessment. Curr Opin Toxicol. 2022;30:100341.
   PubMed Web of Science ®Google Scholar
• Nieskens TTG, Persson M, Kelly EJ, et al. A multicompartment human kidney proximal tubule-on-a-chip replicates cell polarization-dependent cisplatin toxicity. Drug Metab Dispos. 2020;48(12):1303.
   PubMed Web of Science ®Google Scholar
• van der Made Tk, Fedecostante M, Scotcher D, et al. Quantitative translation of microfluidic transporter in vitro data to in vivo reveals impaired albumin-facilitated indoxyl sulfate secretion in chronic kidney disease. Mol Pharm. 2019;16(11):4551–4562.
   PubMedGoogle Scholar